Literature DB >> 1822922

Recent trends of paragonimiasis westermani in Miyazaki Prefecture, Japan.

Y Nawa1.   

Abstract

Miyazaki Prefecture has long been known as one of the endemic areas of paragonimiasis westermani. The prevalence of this disease peaked around 1956 and then drastically decreased. A few sporadic cases are still occasionally found in Miyazaki Prefecture; however, the number of new cases has gradually increased during the last 5 years. One important point to be noted is the change of clinical manifestations in the patients. A classically known form of paragonimiasis westermani is characterized by persisting cough, bloody sputum, and nodular or ring shadows in the lung field by chest x-ray. However, the patients recently found in Miyazaki Prefecture rarely showed such typical symptoms. Only four of 13 cases were found to have pulmonary infiltration and nine cases showed massive pleural effusion without pulmonary infiltration. Such atypical cases may be caused by low intensity of infection or, alternatively, be due to the earlier diagnosis.

Entities:  

Mesh:

Year:  1991        PMID: 1822922

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  3 in total

Review 1.  North American paragonimiasis (Caused by Paragonimus kellicotti) in the context of global paragonimiasis.

Authors:  Gary W Procop
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

2.  Elevated IL-5 levels in pleural fluid of patients with paragonimiasis westermani.

Authors:  H Taniguchi; H Mukae; N Matsumoto; M Tokojima; S Katoh; S Matsukura; K Ogawa; S Kohno; Y Nawa
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

3.  Elevated levels of thymus and activation-regulated chemokine (TARC) in pleural effusion samples from patients infested with Paragonimus westermani.

Authors:  N Matsumoto; H Mukae; F Nakamura-Uchiyama; J-I Ashitani; K Abe; S Katoh; S Kohno; Y Nawa; S Matsukura
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.